MetaCap

Evaxion A/S (EVAX) vs Genenta Science S.p.A. (SAEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Genenta Science S.p.A. is the larger company by market cap ($24.5 million vs $20.8 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVAX-23.99%SAEN-47.19%
+4%-23%-50%
Nov 3, 20261 yearNov 20, 2026
EVAX-25.00%SAEN-23.70%
+1%-13%-26%
Nov 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVAX versus SAEN key metrics
MetricEVAXSAEN
Share price$2.25$0.5074
Market cap$20.75M$24.47M
1-day change+10.84%-9.39%
YTD return-52.83%—
1-year return-56.56%—
5-year return-99.07%—
EPS (TTM)$-1.00$-0.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.53M—
Revenue growth (YoY)+125.12%—
Net income (latest FY)$-7.71M—
Operating margin-122.66%—
Net margin-102.38%—
52-week high$6.92$2.58
52-week low$2.03$0.50
Distance from 52-week high-67.49%-80.33%
Analyst consensusnone—
Avg. price target upside+400.00%—
Average volume85.00K85.01K
Shares outstanding9.22M48.22M
Employees469
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Evaxion A/S

EVAX stock →

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees

About Genenta Science S.p.A.

SAEN stock →

Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 9 employees

EVAX vs SAEN FAQ

Which is bigger, Evaxion A/S or Genenta Science S.p.A.?

Genenta Science S.p.A. (SAEN) is larger, with a market capitalization of $24.47M compared with $20.75M for Evaxion A/S (EVAX).

Are Evaxion A/S and Genenta Science S.p.A. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons